Gilead Sciences News

Gilead Sciences | 8-K: Poll Results of 2024 Annual Meeting of Shareholders

May 9 15:41

Gilead Sciences | 8-K: Gilead Sciences Announces First Quarter 2024 Financial Results

Apr 25 15:09

Gilead Sciences | DEF 14A: Definitive information statements

Mar 28 15:16

Gilead Sciences | DEFA14A: Others

Mar 28 15:11

Gilead Sciences | 8-K: Gilead Sciences Announces Completion of Acquisition of CymaBay Therapeutics and Enters into an Agreement and Plan of Merger with Wholly-Owned Subsidiary Pacific Merger Sub

Mar 22 08:22

Gilead Sciences | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mar 18 15:11

Gilead Sciences | 8-K: Kevin E. Lofton Will Retire from the Board

Mar 14 15:14

Gilead Sciences | 8-K: Agreement and Plan of Merger

Feb 12 07:39

Gilead Sciences | 8-K: Gilead Sciences Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 6 15:10

Gilead Sciences | 8-K: Gilead Sciences Appoints Dr. Ted W. Love to Board of Directors

Feb 2 15:22

Gilead Sciences | 8-K: Gilead Sciences Announces Third Quarter 2023 Financial Results

Nov 7, 2023 15:03

Gilead Sciences | 8-K: Entry into Underwriting Agreements

Sep 14, 2023 08:00

Gilead Sciences | 8-K: Presentation of Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study in WCLC

Aug 16, 2023 16:19

Gilead Sciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Aug 7, 2023 15:23

Gilead Sciences | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

Aug 4, 2023 16:23

Gilead Sciences | 8-K: Gilead Sciences Reports Second Quarter 2023 Financial Results

Aug 3, 2023 15:07

Gilead Sciences | 8-K: Amendment and Restatement Employee Stock Purchase Plan and Voting Results 2023 Annual Meeting of Stockholders

May 5, 2023 10:15

Gilead Sciences | 8-K: GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

Apr 27, 2023 15:05

Gilead Sciences | DEFR14A: Definitive proxy statement in connection with contested solicitations

Apr 5, 2023 15:02

Gilead Sciences | DEF 14A: Definitive proxy statements

Mar 23, 2023 15:06